SEARCH

SEARCH BY CITATION

References

  • 1
    Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care. 2002;25:134147.
  • 2
    Ong KL, Cheung BMY, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension. 2007;49:6975.
  • 3
    Moser M, Franklin SS. Hypertension management: results of a new national survey for the Hypertension Education Foundation: Harris Interactive. J Clin Hypertens (Greenwich). 2007;9(5):316323.
  • 4
    American Diabetes Association. Standards of medical care in diabetes: 2007. Diabetes Care. 2007;30(suppl 1):S4S41.
  • 5
    Sowers JR. Treatment of hypertension in patients with diabetes. Arch Intern Med. 2004;164:18501857.
  • 6
    UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703713.
  • 7
    Bakris GL. The importance of blood pressure control in the patient with diabetes. Am J Med. 2004;116(suppl 5A):30S38S.
  • 8
    Chobanian AV, Bakris GL, Black HR, et al. National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:12061252.
  • 9
    Ritz E, Dikow R. Hypertension and antihypertensive treatment of diabetic nephropathy. Nat Clin Pract Nephrol. 2006;2:562567.
  • 10
    Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease study. Ann Intern Med. 1995;123:754762.
  • 11
    Klahr S, Levey AS, Beck GJ, et al. Modification of Diet in Renal Disease Study Group. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med. 1994;330:877884.
  • 12
    Mugo MN, Sowers JR. Early and aggressive treatment of complex hypertension. J Clin Hypertens (Greenwich). 2005;7:810.
  • 13
    Cushman WC, Grimm RH Jr, Cutler JA, et al. ACCORD Study Group. Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007;99(suppl):44i55i.
  • 14
    Howard BV, Roman MJ, Devereux RB, et al. Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: the SANDS Randomized Trial. JAMA. 2008;299(14):16781689.
  • 15
    Ridker PM, Danielson E, Rifai N, et al. Val-MARC Investigators. Valsartan, blood pressure reduction, and C-reactive protein: primary report of the Val-MARC trial. Hypertension. 2006;48:7379.
  • 16
    Lacourcìre Y, Poirier L, Hebert D, et al. Antihypertensive efficacy and tolerability of two fixed-dose combinations of valsartan and hydrochlorothiazide compared with valsartan monotherapy in patients with stage 2 or 3 systolic hypertension: an 8-week, randomized, double-blind, parallel-group trial. Clin Ther. 2005;27:10131021.
  • 17
    Jamerson KA, Zappe DH, Collins L, et al. The time to blood pressure (BP) control by initiating antihypertensive therapy with a higher dose of valsartan (160 mg) or valsartan/hydrochlorothiazide compared to low-dose valsartan (80 mg) in the treatment of hypertension: the VELOCITY study [ASH abstract P-400]. J Clin Hypertens (Greenwich). 2007;9(suppl A):A166A167.
  • 18
    Chrysant SG, Chrysant GS. The pleiotropic effects of angiotensin receptor blockers. J Clin Hypertens (Greenwich). 2006;8:261268.
  • 19
    Cubbon RM, Rajwani A, Wheatcroft SB. The impact of insulin resistance on endothelial function, progenitor cells and repair. Diab Vasc Dis Res. 2007;4:103111.
  • 20
    Rocchini AP, Moorehead C, DeRemer S, et al. Hyperinsulinemia and the aldosterone and pressor responses to angiotensin II. Hypertension. 1990;15:861866.
  • 21
    Cooper SA, Whaley-Connell A, Habibi J, et al. Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol. 2007;293:H2009H2023.
  • 22
    Bakris GL. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med. 2001;161:26612667.
  • 23
    Giunti S, Cooper M. Management strategies for patients with hypertension and diabetes: why combination therapy is critical. J Clin Hypertens (Greenwich). 2006;8:108113.
  • 24
    Hollenberg NK, Parving H-H, Viberti G, et al. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens. 2007;25:19211926.
  • 25
    Flack JM, Hamaty M. Difficult-to-treat hypertensive populations: focus on African-Americans and people with type 2 diabetes. J Hypertens Suppl. 1999;17(1):S19S24.
  • 26
    Brown MJ, Castaigne A, De Leeuw PW, et al. Influence of diabetes and type of hypertension on response to antihypertensive treatment. Hypertension. 2000;35:10381042.
  • 27
    Sowers JR, Neutel JM, Saunders E, et al. INCLUSIVE Investigators. Antihypertensive efficacy of irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006;8:470480.
  • 28
    Malik S, Lopez V, Chen R, et al. Undertreatment of cardiovascular risk factors among persons with diabetes in the United States. Diabetes Res Clin Pract. 2007;77:126133.
  • 29
    Grant RW, Cagliero E, Dubey AK, et al. Clinical inertia in the management of type 2 diabetes metabolic risk factors. Diabet Med. 2004;21:150155.
  • 30
    Basile J, Black HR, Flack JM, et al. The role of therapeutic inertia and the use of fixed-dose combination therapy in the management of hypertension. J Clin Hypertens (Greenwich). 2007;9:636645.